300006.SZ
Chongqing Lummy Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 9.92
+19.95%Year over year
Reported trailing growth
- Revenue
- -6.6%
- EBITDA
- —
- EBIT
- -20.4%
- EPS
- -40.5%
- Free cash flow
- +129.3%
- Operating cash flow
- -45.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.3%
- EBITDA
- -80.1%
- EBIT
- -38.1%
- Net income
- -53.4%
- EPS
- -53.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026